Inspire Investing LLC Has $414,000 Holdings in Geron Co. (NASDAQ:GERN)

Inspire Investing LLC cut its holdings in shares of Geron Co. (NASDAQ:GERN) by 26.9% during the fourth quarter, Holdings Channel reports. The fund owned 116,860 shares of the biopharmaceutical company’s stock after selling 42,894 shares during the period. Inspire Investing LLC’s holdings in Geron were worth $414,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Readystate Asset Management LP bought a new stake in Geron during the 3rd quarter worth approximately $58,000. Rovin Capital UT ADV bought a new stake in Geron during the 3rd quarter worth approximately $62,000. Empowered Funds LLC bought a new stake in Geron during the 3rd quarter worth approximately $67,000. Inspire Advisors LLC bought a new stake in Geron during the 3rd quarter worth approximately $68,000. Finally, Monterey Private Wealth Inc. bought a new stake in Geron during the 4th quarter worth approximately $63,000. 73.71% of the stock is currently owned by institutional investors.

Geron Stock Down 0.3 %

Shares of Geron stock opened at $3.01 on Friday. The company has a quick ratio of 2.74, a current ratio of 2.89 and a debt-to-equity ratio of 0.04. Geron Co. has a 12 month low of $1.64 and a 12 month high of $5.34. The business has a fifty day simple moving average of $3.59 and a 200 day simple moving average of $4.13. The stock has a market cap of $1.82 billion, a PE ratio of -9.41 and a beta of 0.55.

Geron (NASDAQ:GERN) last announced its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.05. Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. The business had revenue of $28.27 million during the quarter, compared to analysts’ expectations of $18.97 million. During the same period in the previous year, the firm earned ($0.08) earnings per share. The firm’s quarterly revenue was up 17138.4% compared to the same quarter last year. Research analysts predict that Geron Co. will post -0.25 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts recently commented on the company. Barclays upgraded Geron to a “strong-buy” rating in a research report on Friday, November 29th. HC Wainwright reissued a “buy” rating and issued a $9.00 target price on shares of Geron in a research note on Tuesday, December 10th. Needham & Company LLC lifted their target price on Geron from $6.00 to $7.00 and gave the company a “buy” rating in a research note on Monday, January 13th. Finally, Scotiabank started coverage on Geron in a research note on Wednesday, October 16th. They issued a “sector outperform” rating and a $6.00 target price for the company. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $7.25.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.